Determinants of Fat Malabsorption After Roux-en-Y Gastric Bypass

Status Completed

Clinical Trial Summary

The purpose of this study is to determine whether or not the length of the biliopancreatic limb of the Roux-en-Y anastamosis plays a critical role in the development of malabsorption after gastric bypass for treatment of severe obesity.

Clinical Trial Description

Successful surgical treatment of severe obesity by RYGB is believed to require a procedure that (a) restricts the consumption of combustible food energy, and (b) reduces the intestinal absorption of food energy that is consumed. However, with RYGB operations that are currently employed, many patients do not develop the malabsorption they presumably require to produce good long term control of their body weight. It is important to find a way to do RYGB surgery in a way that consistently produces a moderate degree of fat malabsorption.

Patients who are scheduled to receive a RYGB for treatment of severe obesity will be randomly assigned to receive 2 variations of the standard operation. The stomach and duodenal bypass, and the creation of a small gastric pouch will be exactly the same for all patients. There will be differences in the two jejunal limbs which create the Roux-en-Y anastomosis. In Procedure A, the Roux limb length will be 150 cm, and the biliopancreatic limb will contain 40 cm of jejunum. In Procedure B, the Roux limb length will be 110 cm and the biliopancreatic limb will contain 80 cm of jejunum. The total length of jejunum in both limbs is 190 cm in both procedures. Thus, the only difference between procedures A and B is that B procedure has a larger percentage of jejunum in the biliopancreatic limb (80/190=42%) than procedure A (40/190 = 21%). A total of 20 patients will be studied, 10 with each procedure. Before and after RYGB, the patients will be studied in a clinical research laboratory. Dietary intake and intestinal absorption of fat, protein, carbohydrate and combustible energy will be measured by metabolic balance techniques for 72 hours. We hypothesize that fat malabsorption after bypass will be greater and more consistent in patients who receive the longer biliopancreatic limb than in the patients who receive the longer Roux limb. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01252511
Study type	Interventional
Source	Baylor Research Institute
Contact
Status	Completed
Phase	N/A
Start date	January 2011
Completion date	January 14, 2017

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03690752` - Adherence to Walking on an Alter G Anti-Gravity Treadmill	N/A
Active, not recruiting	`NCT02767505` - Bypass Equipoise Sleeve Trial (BEST)	N/A
Recruiting	`NCT05786092` - Impact of Telemonitoring on Metabolic Variables in Severe Obesity	N/A
Active, not recruiting	`NCT03249441` - Compassion-Focused Therapy for People With Severe Obesity.	N/A
Terminated	`NCT04626232` - Comparison of the Sleeve Gastrectomy Technique With a Nissen Fundoplication Added to the Conventional Sleeve Gastrectomy Technique in Morbidly Obese Patients	N/A
Completed	`NCT02952963` - Effect of Bile Acids and Bile Acid Sequstrants on GLP-1 Secretion After Roux-en-Y Gastric Bypass	Phase 4
Active, not recruiting	`NCT02374632` - Gut Hormones as Mediators of Different Weight Loss Responses After Roux-en-Y Gastric Bypass	Phase 4
Active, not recruiting	`NCT04165694` - Single Anastomosis Duodenal Ileal Bypass (SADI) for Sleeve Revision	N/A
Not yet recruiting	`NCT06162715` - GLP-1 Receptor Agonists Post-Bariatric Surgery (GRABS) Feasibility Trial	Phase 2
Completed	`NCT05409612` - Trial Assessing the Immunogenicity and Safety of Two Influenza Vaccine Strategies Among Severe Obese Adult Patients	Phase 3
Completed	`NCT03638895` - Energy Expenditure From ECAL Indirect Calorimeter in a Multicomponent Weight Management Service	N/A
Not yet recruiting	`NCT05493592` - Pigeon Peas (Cajanus Cajan) : a Natural Anti-inflammatory Facilitating Weight Loss in Obese Patients Returning to Sport?	N/A
Completed	`NCT02823561` - Garcinia Mangostana Extracts in the Management of Weight Loss	Phase 4
Completed	`NCT02340247` - Effects of Bile Acids on GLP-1 Secretion After Roux-en-Y Gastric Bypass	Phase 4
Recruiting	`NCT02076880` - SLEEVEDIAB To Explore the Early and Late Metabolic Effects of Sleeve Gastrectomy in Obese Patients	N/A
Completed	`NCT04042493` - Connect for Health Pediatric Weight Management Program	N/A
Completed	`NCT04129801` - Muscle Strength in Severe Obese Patients in the Postoperative of Bariatric Surgery
Completed	`NCT05341414` - Trajectories of Resilience and Bariatric Surgery Outcomes
Recruiting	`NCT02710786` - Comorbidity After Gastric Bypass
Recruiting	`NCT02409160` - Sleep and Immune Response in Severe Obese Patients Undergoing Bariatric Surgery.	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.